Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian Federation

Withdrawn

Conditions: Gastroesophageal Reflux Disease

First Posted Date: 2020-03-17

Last Posted Date: 2020-04-14

Lead Sponsor: Takeda

Registration Number: NCT04311541

Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Trelagliptin

First Posted Date: 2020-02-26

Last Posted Date: 2024-08-23

Lead Sponsor: Takeda

Target Recruit Count: 89

Registration Number: NCT04285983

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Phase 2

Completed

Conditions: Primary Immune Thrombocytopenia

Interventions: Drug: TAK-079
Drug: Placebo

First Posted Date: 2020-02-20

Last Posted Date: 2024-10-14

Lead Sponsor: Takeda

Target Recruit Count: 41

Registration Number: NCT04278924

Locations: 🇧🇬
Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda, Sofia, Sofia-Grad, Bulgaria
🇸🇮
Univerzitetni klinicni Center Ljubljana, Ljubljana, Slovenia
🇧🇬
University Mulitiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria

and more 52 locations

A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Phase 1

Terminated

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2020-02-17

Last Posted Date: 2020-03-17

Lead Sponsor: Takeda

Target Recruit Count: 14

Registration Number: NCT04272775

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Venetoclax
Drug: Pevonedistat
Drug: Azacitidine

First Posted Date: 2020-02-12

Last Posted Date: 2024-12-17

Lead Sponsor: Takeda

Target Recruit Count: 164

Registration Number: NCT04266795

Locations: 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
🇺🇸
UC Irvine Medical Center, Orange, California, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 54 locations

Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

Phase 1

Withdrawn

Conditions: Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma
Solid Tumors
Inflammatory Myofibroblastic Tumors

Interventions: Drug: Brigatinib
Drug: Brigatinib AAF

First Posted Date: 2020-02-07

Last Posted Date: 2020-03-05

Lead Sponsor: Takeda

Registration Number: NCT04260009

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

Completed

Conditions: Peripheral T Cell Lymphoma
Pediatric Hodgkin Lymphoma

Interventions: Drug: Brentuximab Vedotin (Genetical Recombination)

First Posted Date: 2019-12-30

Last Posted Date: 2024-01-16

Lead Sponsor: Takeda

Target Recruit Count: 95

Registration Number: NCT04213209

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Phase 3

Completed

Conditions: Angioedema

Interventions: Other: Placebo
Drug: Lanadelumab

First Posted Date: 2019-12-20

Last Posted Date: 2023-12-27

Lead Sponsor: Takeda

Target Recruit Count: 77

Registration Number: NCT04206605

Locations: 🇺🇸
University of South Florida Asthma, Allergy & Immunology, Tampa, Florida, United States
🇩🇪
Universitaetsklinikum Leipzig AoeR, Leipzig, Sachsen, Germany
🇺🇸
Medical Research of Arizona, Scottsdale, Arizona, United States

and more 42 locations

A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: TAK-418
Drug: [18F]MNI-1054 (radiotracer)

First Posted Date: 2019-12-17

Last Posted Date: 2021-07-30

Lead Sponsor: Takeda

Target Recruit Count: 7

Registration Number: NCT04202497

Locations: 🇺🇸
Invicro, A Konica Minolta Company, New Haven, Connecticut, United States

A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

Phase 3

Completed

Conditions: Helicobacter Pylori

Interventions: Drug: Vonoprazan
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Bismuth Potassium citrate
Drug: Esomeprazole

First Posted Date: 2019-12-13

Last Posted Date: 2023-09-07

Lead Sponsor: Takeda

Target Recruit Count: 510

Registration Number: NCT04198363

Locations: 🇨🇳
The First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳
Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

and more 26 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy